{"symbol":"BMY","fiscalQuarter":"Q1-2022","reportDate":"2022-04-29","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q1-2022","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 2.5%","keyNumbers":[{"metric":"EPS","actual":"$1.96","expected":"N/A","surprise":"+2.35%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing commitment to innovation in drug development.","They emphasized the importance of maintaining strong operational performance."],"summary":"Overall, management expressed confidence in their pipeline and future growth. However, they acknowledged challenges in the current market environment."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 2.5% following the announcement, likely due to the lack of revenue details and guidance. Investors may be cautious given the uncertainties in the market and the absence of forward-looking statements from management.","metaDescription":"Bristol Myers Squibb (BMY) Q1 2022 earnings: EPS beat by 2.35%. Stock down 2.5%. Full breakdown."}}